Chroma Medicine, Inc. — Form D/A
Chroma Medicine, Inc. of BOSTON, MA, a company, filed a Form D amendment with the SEC on 2023-09-01. The offering totals $135.0M, of which $135.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-09-01
- Form: D/A
- Accession: 0001802806-23-000011
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $135.0M
- Amount sold: $135.0M
- Investors: 21
- Date of first sale: 2023-02-08
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-474618
Issuer
- Name: Chroma Medicine, Inc.
- CIK: 0001967386
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 201 BROOKLINE AVE, BOSTON, MA, 02215
- Phone: 617-714-5547
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Kevin Bitterman | Director | Cambridge, MA |
| Thomas Cahill | Director | Boston, MA |
| BIHUA CHEN | Director | Boston, MA |
| GEORGE GOLUMBESKI | Director | BOSTON, MA |
| Michael Kelly | Director | NEW YORK, NY |
| JEFF MARRAZZO | Director | BOSTON, MA |
| PAOLA POZZI | Director | BOSTON, MA |
| CATHERINE STEHMAN-BREEN | Director | BOSTON, MA |
| BRETT KAPLAN | Executive Officer | BOSTON, MA |
| VIC MYER | Executive Officer | BOSTON, MA |
| CATHERINE STEHMAN-BREEN | Executive Officer | BOSTON, MA |
Other filings by this issuer (1)
More